Celcuity (NASDAQ:CELC) Given New $134.00 Price Target at Jefferies Financial Group

Celcuity (NASDAQ:CELC) had its target price upped by Jefferies Financial Group from $108.00 to $134.00 in a report released on Tuesday morning,Benzinga reports. Jefferies Financial Group currently has a buy rating on the stock.

Other research analysts also recently issued research reports about the stock. Stifel Nicolaus increased their price objective on shares of Celcuity from $68.00 to $115.00 and gave the company a “buy” rating in a report on Thursday, November 13th. Needham & Company LLC set a $95.00 target price on Celcuity in a research report on Monday, October 20th. HC Wainwright restated a “neutral” rating and set a $94.00 price target (up previously from $77.00) on shares of Celcuity in a report on Monday, November 17th. Guggenheim assumed coverage on Celcuity in a research note on Monday, September 22nd. They issued a “buy” rating on the stock. Finally, Wolfe Research initiated coverage on Celcuity in a research report on Tuesday, November 18th. They set an “outperform” rating and a $110.00 target price for the company. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $102.29.

Celcuity Trading Down 1.0%

Celcuity stock opened at $97.50 on Tuesday. Celcuity has a 12-month low of $7.57 and a 12-month high of $103.06. The firm has a market capitalization of $4.51 billion, a price-to-earnings ratio of -26.57 and a beta of 0.21. The firm has a 50 day moving average of $71.64 and a 200 day moving average of $44.46. The company has a current ratio of 12.26, a quick ratio of 12.26 and a debt-to-equity ratio of 2.74.

Celcuity (NASDAQ:CELC) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.92) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.13. As a group, research analysts predict that Celcuity will post -2.62 earnings per share for the current year.

Insider Buying and Selling

In other Celcuity news, Director Richard E. Buller sold 3,900 shares of Celcuity stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $96.73, for a total transaction of $377,247.00. Following the completion of the transaction, the director directly owned 7,260 shares of the company’s stock, valued at $702,259.80. The trade was a 34.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 15.78% of the stock is owned by insiders.

Hedge Funds Weigh In On Celcuity

A number of large investors have recently made changes to their positions in CELC. Ogorek Anthony Joseph NY ADV purchased a new stake in Celcuity in the 3rd quarter worth about $27,000. US Bancorp DE grew its stake in shares of Celcuity by 25.4% during the third quarter. US Bancorp DE now owns 706 shares of the company’s stock valued at $35,000 after buying an additional 143 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Celcuity by 78.9% in the second quarter. BNP Paribas Financial Markets now owns 2,647 shares of the company’s stock worth $35,000 after buying an additional 1,167 shares during the period. Tower Research Capital LLC TRC lifted its stake in shares of Celcuity by 211.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,549 shares of the company’s stock worth $74,000 after acquiring an additional 3,766 shares during the last quarter. Finally, Avanza Fonder AB bought a new stake in shares of Celcuity during the 3rd quarter worth approximately $79,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.